Completed PHASE4 INTERVENTIONAL 2-arm NCT00606515

Pharmacokinetics Study of Liposomal Paclitaxel in Humans (LPS-PK-H)

A Clinical Trial to Compare the Pharmacokinetics of Two Formulations of Taxane, Paclitaxel Injection and Liposomal Paclitaxel, in Humans

Sponsor: Nanjing Sike Pharmaceutical Co., Ltd.

Conditions Cancer

Interventions Liposomal paclitaxel Paclitaxel

Updated 5 times since 2017 Last updated: Feb 9, 2009 Started: Feb 29, 2008 Primary completion: Oct 31, 2008 Completion: Oct 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00606515, this PHASE4 trial focuses on Cancer and remains completed. Sponsored by Nanjing Sike Pharmaceutical Co., Ltd., it has been updated 5 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nanjing Sike Pharmaceutical Co., Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Data source: Shandong Luye Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China